Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Colorectal Neoplasms 29Prostatic Neoplasms 28Neoplasms 28Breast Neoplasms 27Neoplasm Metastasis 26Multiple Myeloma 24Pancreatic Neoplasms 22Recurrence 18Ovarian Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Melanoma 17Lymphoma, Non-Hodgkin 17Triple Negative Breast Neoplasms 16Lymphoma, Large B-Cell, Diffuse 15Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Burkitt Lymphoma 14Lung Neoplasms 13Carcinoma, Renal Cell 13Stomach Neoplasms 12Lymphoma, Follicular 12Lymphoma 12Endometrial Neoplasms 12Advanced Solid Tumors 12Small Cell Lung Carcinoma 11Glioblastoma 11Colonic Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 10Uterine Cervical Neoplasms 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Dendritic Cell Sarcoma, Interdigitating × 30 days × Clear all
NCT07249905 2026-05-04

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

ModeX Therapeutics, An OPKO Health Company

Phase 1/2 Recruiting
180 enrolled
LymphoidSarcoma

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡